Heparin: A potent inhibitor of hepcidin expression in vitro and in vivo

Blood

Volumn 117, Issue 3, 2011, Pages 997-1004

  Poli, Maura ^a   Girelli, Domenico ^b   Campostrini, Natascia ^b   Maccarinelli, Federica ^a   Finazzi, Dario ^a,c   Luscieti, Sara ^a   Nai, Antonella ^d   Arosio, Paolo ^a,c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SPEDALI CIVILI   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; C REACTIVE PROTEIN; HEPARIN; HEPCIDIN; IRON; MESSENGER RNA; SMAD PROTEIN;

ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; ERYTHROPOIESIS; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; IRON DEFICIENCY ANEMIA; LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN;

EID: 78751696745     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-289082     Document Type: Article

References (55)

1. Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol.2010:750643.
2. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783-788. (Pubitemid 36917762)
3. Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis. 2008;40(1):132-138. (Pubitemid 350192311)
4. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093.
5. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122(2-3):78-86.
6. Nicolas G, Andrews NC, Kahn A, Vaulont S. Hepcidin, a candidate modifier of the hemochromatosis phenotype in mice. Blood. 2004;103(7):2841-2843. (Pubitemid 38393048)
7. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117(7):1933-1939.
8. Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38(5):531-539.
9. Silvestri L, Guillem F, Pagani A, et al. Molecular mechanisms of the defective hepcidin inhibition in TMPRSS6 mutations associated with iron-refractory iron deficiency anemia. Blood. 2009;113(22):5605-5608.
10. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008;8(6):502-511.
11. Truksa J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci U S A. 2006;103(27):10289-10293.
12. Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol. 2008;4(1):33-41.
13. Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41(4):482-487.
14. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet. 2009;41(4):478-481.
15. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109(1):353-358.
16. Huang H, Constante M, Layoun A, Santos M. Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood. 2009;113(15):3593-3599.
17. Wrighting D, Andrews N. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204-3209.
18. Wang RH, Li C, Xu X, et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2005;2(6):399-409.
19. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem. 2010;147(1):35-51.
20. Irie A, Habuchi H, Kimata K, Sanai Y. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun. 2003;308(4):858-865. (Pubitemid 36976539)
21. Hausser HJ, Brenner RE. Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro. J Cell Biochem. 2004;91(5):1062-1073.
22. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22(4):233-241.
23. Turnbull J, Powell A, Guimond S. Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 2001;11(2):75-82. (Pubitemid 32144754)
24. Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002;99(4):1405-1410.
25. Fisher MC, Li Y, Seghatoleslami MR, Dealy CN, Kosher RA. Heparan sulfate proteoglycans including syndecan-3 modulate BMP activity during limb cartilage differentiation. Matrix Biol. 2006;25(1):27-39. (Pubitemid 43145809)
26. Hu Z, Wang C, Xiao Y, et al. NDST1-dependent heparan sulfate regulates BMP signaling and internalization in lung development. J Cell Sci. 2009;122(Pt 8):1145-1154.
27. Jasuja R, Allen BL, Pappano WN, Rapraeger AC, Greenspan DS. Cell-surface heparan sulfate proteoglycans potentiate chordin antagonism of bone morphogenetic protein signaling and are necessary for cellular uptake of chordin. J Biol Chem. 2004;279(49):51289-51297.
28. Jiao X, Billings PC, O'Connell MP, Kaplan FS, Shore EM, Glaser DL. Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem. 2007;282(2):1080-1086.
29. Presta M, Leali D, Stabile H, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des. 2003;9(7):553-566.
30. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science. 1988;242(4885):1528-1534. (Pubitemid 19023695)
31. Zhao B, Katagiri T, Toyoda H, et al. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem. 2006;281(32):23246-23253.
32. Takada T, Katagiri T, Ifuku M, et al. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem. 2003;278(44):43229-43235.
33. Zhou H, Qian J, Wang J, et al. Enhanced bioactivity of bone morphogenetic protein-2 with low dose of 2-N,6-O-sulfated chitosan in vitro and in vivo. Biomaterials. 2009;30(9):1715-1724.
34. Kanzaki S, Takahashi T, Kanno T, et al. Heparin inhibits BMP-2 osteogenic bioactivity by binding to both BMP-2 and BMP receptor. J Cell Physiol. 2008;216(3):844-850.
35. Rusnati M, Oreste P, Zoppetti G, Presta M. Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. Curr Pharm Des. 2005;11(19):2489-2499.
36. Rusnati M, Urbinati C. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr Pharm Des. 2009;15(25):2946-2957.
37. Roetto A, Di Cunto F, Pellegrino R, et al. Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues. Blood. 2010;115(16):3382-3389.
38. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
39. Swinkels DW, Girelli D, Laarakkers C, et al. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS ONE. 2008;3(7):e2706.
40. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-1276.
41. Coltrini D, Rusnati M, Zoppetti G, et al. Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochem J. 1994;303(Pt 2):583-590. (Pubitemid 24317343)
42. Rusnati M, Tulipano G, Spillmann D, et al. Multiple interactions of HIV-I Tat protein with sizedefined heparin oligosaccharides. J Biol Chem. 1999;274(40):28198-28205.
43. Ramey G, Deschemin JC, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica. 2010;95(3):501-504.
44. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem. 2004;279(13):12346-12354. (Pubitemid 38445801)
45. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem. 1996;237(1):295-302. (Pubitemid 26110301)
46. Griffith GC, Nichols G Jr, Asher JD, Flanagan B. Heparin Osteoporosis. JAMA. 1965;193:91-94.
47. Khan SA, Nelson MS, Pan C, Gaffney PM, Gupta P. Endogenous heparan sulfate and heparin modulate bone morphogenetic protein-4 signaling and activity. Am J Physiol Cell Physiol. 2008;294(6):C1387-1397.
48. Hoppensteadt D, Fareed J, Klein AL, et al. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation. Am J Cardiol. 2008;102(7):842-846.
49. Braunsteiner H, Sailer S, Weippl W. On the influence of nicotinic acid and heparin on iron metabolism. Blut. 1959;5:149-154.
50. Li JP, Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost. 2009;102(5):823-828.
51. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis. 2010;55(4):726-741.
52. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of in- flammation-induced anemia. Blood. 2010;115(17):3616-3624.
53. Pinto JP, Ribeiro S, Pontes H, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signalling and regulation of C/EBP{alpha}. Blood. 2008;111(12):5727-33.
54. Ceccarelli M, Bani D, Cinci L, et al. Antiinflammatory effects of low molecular weight heparin derivative in a rat model of carrageenan-induced pleurisy. J Cell Mol Med. 2009;13(8b):2704-2712.
55. Rusnati M, Vicenzi E, Donalisio M, Oreste P, Landolfo S, Lembo D. Sulfated K5 Escherichia coli polysaccharide derivatives: a novel class of candidate antiviral microbicides. Pharmacol Ther. 2009;123(3):310-322.